Current and future perspectives on the TARGET system

The registration system for Glivec® established by the JSH

Masahiro Kizaki, Shinichiro Okamoto, Tetsuzo Tauchi, Hideo Tanaka, Mitsune Tanimoto, Koiti Inokuchi, Tohru Murayama, Yoshio Saburi, Masayuki Hino, Mitsuru Tsudo, Taizo Shimomura, Yasushi Isobe

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Since hematology is a highly specialized field, an individual physician may not have much direct treatment experience with a given disease. Therefore, the Japanese Society of Hematology (JSH) has discussed establishing a registry of hematologic disorders, in order to contribute to improving the quality of treatments and clinical outcomes in this field. As a first step, the Timely and Appropriate Registration System for GLIVEC Therapy (TARGET), a registration system for chronic myeloid leukemia (CML) patients treated with imatinib, was established in October 2003. We present the preliminary results of the first 4 years' experience with this system. CML patients treated with imatinib in Japan were registered through the website and the patient's clinical course, including parameters and events like imatinib dose, blood counts, adverse events, and efficacy were recorded in months 1, 3, 6, 9, and 12 and then every 6 months thereafter. By September 2007, 862 patients from 176 hospitals were registered. Follow-up period was 0-54 months, and 127 patients were followed-up for more than 36 months. Based on these cumulative data, present imatinib treatment trends were analyzed and safety and efficacy were compared with international trial data.

Original languageEnglish
Pages (from-to)409-417
Number of pages9
JournalInternational Journal of Hematology
Volume88
Issue number4
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Hematology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Registries
Japan
Imatinib Mesylate
Physicians
Safety

Keywords

  • CML
  • Glivec
  • IRIS study
  • JSH
  • Registration
  • TARGET

ASJC Scopus subject areas

  • Hematology

Cite this

Current and future perspectives on the TARGET system : The registration system for Glivec® established by the JSH. / Kizaki, Masahiro; Okamoto, Shinichiro; Tauchi, Tetsuzo; Tanaka, Hideo; Tanimoto, Mitsune; Inokuchi, Koiti; Murayama, Tohru; Saburi, Yoshio; Hino, Masayuki; Tsudo, Mitsuru; Shimomura, Taizo; Isobe, Yasushi.

In: International Journal of Hematology, Vol. 88, No. 4, 11.2008, p. 409-417.

Research output: Contribution to journalArticle

Kizaki, M, Okamoto, S, Tauchi, T, Tanaka, H, Tanimoto, M, Inokuchi, K, Murayama, T, Saburi, Y, Hino, M, Tsudo, M, Shimomura, T & Isobe, Y 2008, 'Current and future perspectives on the TARGET system: The registration system for Glivec® established by the JSH', International Journal of Hematology, vol. 88, no. 4, pp. 409-417. https://doi.org/10.1007/s12185-008-0186-0
Kizaki, Masahiro ; Okamoto, Shinichiro ; Tauchi, Tetsuzo ; Tanaka, Hideo ; Tanimoto, Mitsune ; Inokuchi, Koiti ; Murayama, Tohru ; Saburi, Yoshio ; Hino, Masayuki ; Tsudo, Mitsuru ; Shimomura, Taizo ; Isobe, Yasushi. / Current and future perspectives on the TARGET system : The registration system for Glivec® established by the JSH. In: International Journal of Hematology. 2008 ; Vol. 88, No. 4. pp. 409-417.
@article{d20433f44a8041958a0ed488a882c976,
title = "Current and future perspectives on the TARGET system: The registration system for Glivec{\circledR} established by the JSH",
abstract = "Since hematology is a highly specialized field, an individual physician may not have much direct treatment experience with a given disease. Therefore, the Japanese Society of Hematology (JSH) has discussed establishing a registry of hematologic disorders, in order to contribute to improving the quality of treatments and clinical outcomes in this field. As a first step, the Timely and Appropriate Registration System for GLIVEC Therapy (TARGET), a registration system for chronic myeloid leukemia (CML) patients treated with imatinib, was established in October 2003. We present the preliminary results of the first 4 years' experience with this system. CML patients treated with imatinib in Japan were registered through the website and the patient's clinical course, including parameters and events like imatinib dose, blood counts, adverse events, and efficacy were recorded in months 1, 3, 6, 9, and 12 and then every 6 months thereafter. By September 2007, 862 patients from 176 hospitals were registered. Follow-up period was 0-54 months, and 127 patients were followed-up for more than 36 months. Based on these cumulative data, present imatinib treatment trends were analyzed and safety and efficacy were compared with international trial data.",
keywords = "CML, Glivec, IRIS study, JSH, Registration, TARGET",
author = "Masahiro Kizaki and Shinichiro Okamoto and Tetsuzo Tauchi and Hideo Tanaka and Mitsune Tanimoto and Koiti Inokuchi and Tohru Murayama and Yoshio Saburi and Masayuki Hino and Mitsuru Tsudo and Taizo Shimomura and Yasushi Isobe",
year = "2008",
month = "11",
doi = "10.1007/s12185-008-0186-0",
language = "English",
volume = "88",
pages = "409--417",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Current and future perspectives on the TARGET system

T2 - The registration system for Glivec® established by the JSH

AU - Kizaki, Masahiro

AU - Okamoto, Shinichiro

AU - Tauchi, Tetsuzo

AU - Tanaka, Hideo

AU - Tanimoto, Mitsune

AU - Inokuchi, Koiti

AU - Murayama, Tohru

AU - Saburi, Yoshio

AU - Hino, Masayuki

AU - Tsudo, Mitsuru

AU - Shimomura, Taizo

AU - Isobe, Yasushi

PY - 2008/11

Y1 - 2008/11

N2 - Since hematology is a highly specialized field, an individual physician may not have much direct treatment experience with a given disease. Therefore, the Japanese Society of Hematology (JSH) has discussed establishing a registry of hematologic disorders, in order to contribute to improving the quality of treatments and clinical outcomes in this field. As a first step, the Timely and Appropriate Registration System for GLIVEC Therapy (TARGET), a registration system for chronic myeloid leukemia (CML) patients treated with imatinib, was established in October 2003. We present the preliminary results of the first 4 years' experience with this system. CML patients treated with imatinib in Japan were registered through the website and the patient's clinical course, including parameters and events like imatinib dose, blood counts, adverse events, and efficacy were recorded in months 1, 3, 6, 9, and 12 and then every 6 months thereafter. By September 2007, 862 patients from 176 hospitals were registered. Follow-up period was 0-54 months, and 127 patients were followed-up for more than 36 months. Based on these cumulative data, present imatinib treatment trends were analyzed and safety and efficacy were compared with international trial data.

AB - Since hematology is a highly specialized field, an individual physician may not have much direct treatment experience with a given disease. Therefore, the Japanese Society of Hematology (JSH) has discussed establishing a registry of hematologic disorders, in order to contribute to improving the quality of treatments and clinical outcomes in this field. As a first step, the Timely and Appropriate Registration System for GLIVEC Therapy (TARGET), a registration system for chronic myeloid leukemia (CML) patients treated with imatinib, was established in October 2003. We present the preliminary results of the first 4 years' experience with this system. CML patients treated with imatinib in Japan were registered through the website and the patient's clinical course, including parameters and events like imatinib dose, blood counts, adverse events, and efficacy were recorded in months 1, 3, 6, 9, and 12 and then every 6 months thereafter. By September 2007, 862 patients from 176 hospitals were registered. Follow-up period was 0-54 months, and 127 patients were followed-up for more than 36 months. Based on these cumulative data, present imatinib treatment trends were analyzed and safety and efficacy were compared with international trial data.

KW - CML

KW - Glivec

KW - IRIS study

KW - JSH

KW - Registration

KW - TARGET

UR - http://www.scopus.com/inward/record.url?scp=64249086107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249086107&partnerID=8YFLogxK

U2 - 10.1007/s12185-008-0186-0

DO - 10.1007/s12185-008-0186-0

M3 - Article

VL - 88

SP - 409

EP - 417

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -